adenosine monophosphate has been researched along with Disease Exacerbation in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 18 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelghany, M; Behenna-Renton, N; Brown, M; Brown, SM; Camus, G; Chen, S; Davies, S; Duff, F; Ginde, AA; Gottlieb, RL; Hidalgo, A; Hill, JA; Hyland, RH; Juneja, K; Katz, MJ; Marty, FM; Mera, J; Mittal, S; Nielsen, BU; Oguchi, G; Osinusi, A; Osiyemi, O; Paredes, R; Perez, G; Ryan, P; Sachdeva, Y; Schiffer, JT; Skarbinski, J; Vaca, CE; Webb, BJ | 1 |
| Barbieri, C; Caroselli, C; Della Sala, L; Falcone, M; Forniti, A; Galfo, V; Giusti, L; Menichetti, F; Monzani, F; Okoye, C; Suardi, LR; Tempini, S; Tiseo, G | 1 |
| Adler, JM; Ambiel, I; Bartenschlager, R; Boulant, S; Bushe, J; Chlanda, P; Cortese, M; Diaz, RS; Fackler, OT; Fares, M; Fathy, M; Gallucci, L; Gruber, AD; Laketa, V; Lucic, B; Lusic, M; Neufeldt, CJ; Savarino, A; Shytaj, IL; Sobhy, MH; Stanifer, ML; Stolp, B; Sutton, RE; Taha Ayoub, A; Tolba, MM; Trimpert, J; Xing, N; Zhao, M; Zimmermann, L | 1 |
| Addo, MM; Aepfelbacher, M; Fischer, N; Grundhoff, A; Günther, T; Heyer, A; Jarczak, D; Kluge, S; Lütgehetmann, M; Robitaille, A; Schulze Zur Wiesch, J | 1 |
| Bange, H; Batchuluun, B; Blockken, L; Buchholz, B; Dagorn, PG; Hallakou-Bozec, S; Kraus, A; Moller, DE; Steinberg, GR | 1 |
| Cho, JY; Kim, B; Kim, H; Kim, HS | 1 |
| Benaki, D; Giannopoulou, AF; Gikas, E; Iliou, A; Konstantakou, EG; Kosmopoulou, M; Mikros, E; Panagiotakis, A; Papassideri, IS; Stravopodis, DJ; Tsitsilonis, OE; Velentzas, AD; Voutsinas, GE | 1 |
| Ge, J; Li, H; Liu, Z | 1 |
| Anzick, S; Barbian, K; Bosio, CM; Cihlar, T; de Wit, E; Feldmann, F; Hanley, PW; Leighton, I; Lovaglio, J; Martens, C; Meade-White, K; Munster, VJ; Okumura, A; Pérez-Pérez, L; Porter, DP; Saturday, G; Schulz, J; Schwarz, B; Scott, DP; van Doremalen, N; Williamson, BN; Yinda, CK | 1 |
| Cleland, E; Giovane, RA; Henderson, CE; Rezai, S | 1 |
| Briasoulis, A; Kuno, T; Takagi, H; Yokoyama, Y | 1 |
| Amézaga Menéndez, R; Catalán González, M; Díaz, E; Escapa, MG; Marcos Neira, P; Quintana Díaz, M; Serrano Lázaro, A; Suberviola, B; Vidal Cortés, P | 1 |
| Alcobendas, R; Álvarez-Rojas, E; de la Serna, O; Laplaza-González, M; Murias, S; Quintana-Ortega, C; Remesal, A; Ruiz de Valbuena, M; Udaondo, C | 1 |
| Trkulja, V | 1 |
| Arbel, Y; Banai, A; Banai, S; Borohovitz, A; Furie, N; Gal-Oz, A; Ghantous, E; Granot, Y; Hochstadt, A; Ingbir, M; Lichter, Y; Lupu, L; Merdler, I; Sapir, O; Szekely, Y; Taieb, P; Topilsky, Y | 1 |
| Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Kutsuna, S | 1 |
| Ansems, K; Benstoem, C; Dahms, K; Fichtner, F; Grundeis, F; Metzendorf, MI; Mikolajewska, A; Piechotta, V; Stegemann, M; Thieme, V | 1 |
| Alves de Inda, M; Baillie, GS; Bangma, C; den Biezen-Timmermans, E; Hoffmann, R; Houslay, MD; Schlomm, T; Tennstedt, P; van Brussel, A; van Strijp, D; van Zon, H; Vos, P; Wrobel, J | 1 |
| Boban, M; Bobana, MD; Cvetkovic, T; Deljanin-Ilic, M; Djindjic, B; Ilic, S; Jevtovic-Stoimenov, T; Kocic, G; Pavlovic, R; Radenkovic, S; Sokolovic, D; Stojanovic, D | 1 |
| Rogge, MM | 1 |
| Ayscue, LH; Jin, A; Lazarowski, E; Mitchell, BS; Ostapkowicz, A; Spychala, J | 1 |
| Cosi, C; Fluit, P; Gallo-Hendrikx, E; Marien, MR; Martel, JC; Mount, HT; Wu, Y | 1 |
| Cronin, C; Gongora Nieto, M; Harrison, D; Jacobson, KA; Joshi, BV; Liang, BT; Shen, JB; Sonin, D | 1 |
| Feldman, AM; McNamara, DM; Wagner, DR | 1 |
| DeNofrio, D; Holmes, EW; Loh, E; Mahoney, PD; Rebbeck, TR; Swain, JL | 1 |
7 review(s) available for adenosine monophosphate and Disease Exacerbation
| Article | Year |
|---|---|
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Administration Schedule; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2020 |
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Disease Progression; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunomodulation; Interferon-beta; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ritonavir; SARS-CoV-2 | 2021 |
[COVID-19: From a clinician's perspective.]
Topics: Adenosine Monophosphate; Alanine; COVID-19; Disease Progression; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Polymerase Chain Reaction; Risk Factors; SARS-CoV-2; Sputum; Time Factors | 2020 |
Remdesivir for the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Bias; Cause of Death; Confidence Intervals; COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Middle Aged; Oxygen; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Ventilator Weaning | 2021 |
The role of impaired mitochondrial lipid oxidation in obesity.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Causality; Disease Progression; Energy Metabolism; Exercise; Fatigue; Fatty Acids; Glycolysis; Homeostasis; Humans; Lipid Metabolism; Lipolysis; Liver; Mitochondria, Muscle; Mitochondrial Diseases; Models, Biological; Obesity; Oxidation-Reduction; Oxidative Stress; Physical Endurance | 2009 |
1 trial(s) available for adenosine monophosphate and Disease Exacerbation
| Article | Year |
|---|---|
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Comorbidity; COVID-19; COVID-19 Drug Treatment; Disease Progression; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Outpatients; SARS-CoV-2; Time-to-Treatment; Viral Load | 2022 |
18 other study(ies) available for adenosine monophosphate and Disease Exacerbation
| Article | Year |
|---|---|
Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Disease Progression; Humans; Pneumonia; Prospective Studies | 2022 |
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cobicistat; COVID-19 Drug Treatment; Cricetinae; Disease Progression; Hepatitis C, Chronic; Humans; Mesocricetus; Pandemics; SARS-CoV-2; Viral Load | 2022 |
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19 Drug Treatment; Disease Progression; Humans; Pandemics; Pneumonia, Viral; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2 | 2022 |
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Cysts; Disease Progression; Dogs; Kidney; Mice; Mice, Knockout; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency; TRPP Cation Channels | 2023 |
Nicotinamide attenuates the decrease in dendritic spine density in hippocampal primary neurons from 5xFAD mice, an Alzheimer's disease animal model.
Topics: Adenosine Monophosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Dendritic Spines; Disease Models, Animal; Disease Progression; Female; Hippocampus; Lysophosphatidylcholines; Lysophospholipids; Male; Metabolomics; Mice, Transgenic; Mutation, Missense; Neurons; Niacinamide; Peptide Fragments; Point Mutation; Presenilin-1 | 2020 |
Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.
Topics: Adenosine Monophosphate; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cell Line, Tumor; Disease Progression; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Metabolic Networks and Pathways; Metabolomics; Neoplasm Grading; Phosphocreatine; Thymosin; Urinary Bladder Neoplasms | 2020 |
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Betacoronavirus; Bronchoalveolar Lavage Fluid; Coronavirus Infections; COVID-19; Disease Models, Animal; Disease Progression; DNA Mutational Analysis; Drug Resistance, Viral; Female; Lung; Macaca mulatta; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2; Secondary Prevention; Time Factors; Viral Load; Virus Replication; Virus Shedding | 2020 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Autoantibodies; Bronchoscopy; Child; COVID-19; COVID-19 Nucleic Acid Testing; Cyclophosphamide; Dermatomyositis; Disease Progression; Fatal Outcome; Female; Humans; Hydroxychloroquine; Immunocompromised Host; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Interferon-Induced Helicase, IFIH1; Lung; Lung Diseases, Interstitial; Lymphohistiocytosis, Hemophagocytic; Mediastinal Emphysema; Methylprednisolone; Piperidines; Pneumonia, Pneumocystis; Pneumothorax; Pyrimidines; Respiratory Insufficiency; Shock, Septic; Subcutaneous Emphysema; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Topics: Adenosine Monophosphate; Airway Management; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Humans; Hypoxia; Mortality; Patient Selection; Pneumonia, Viral; Randomized Controlled Trials as Topic; Respiratory Insufficiency; SARS-CoV-2; Time-to-Treatment; Treatment Outcome | 2021 |
COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes.
Topics: Adenosine Monophosphate; Adult; Age Distribution; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Disease Progression; Female; Hospitalization; Humans; Immunization, Passive; Male; Middle Aged; Respiration, Artificial; Retrospective Studies; Sex Distribution | 2021 |
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine | 2021 |
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Topics: Adenosine Monophosphate; Biomarkers; Clinical Decision-Making; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Male; Postoperative Period; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Salvage Therapy | 2018 |
Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood Pressure; Creatinine; Disease Progression; Essential Hypertension; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Renal Dialysis; Urea; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 2014 |
Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; Adenosine Monophosphate; Adenosine Triphosphate; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Progression; Estradiol; Estrogens; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Phorbol Esters; Plasmids; Receptors, Estrogen; RNA, Messenger; Time Factors; Transfection | 2004 |
Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Catecholamines; Cell Cycle Proteins; Cerebellum; Corpus Striatum; Disease Models, Animal; Disease Progression; DNA-Binding Proteins; Dopamine; Mesencephalon; Mice; Mice, Knockout; NAD; NADP; Protein Serine-Threonine Kinases; Psychomotor Performance; Sex Factors; Tumor Suppressor Proteins | 2004 |
P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.
Topics: Adenine Nucleotides; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Benzenesulfonates; Calsequestrin; Cardiac Output, Low; Cardiomyopathies; Disease Models, Animal; Disease Progression; Membrane Potentials; Mice; Mice, Transgenic; Myocytes, Cardiac; Patch-Clamp Techniques; Purinergic P2 Receptor Agonists; Pyridoxal Phosphate; Receptors, Purinergic P2; Receptors, Purinergic P2X4; Thionucleotides | 2007 |
AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression.
Topics: Adenosine; Adenosine Monophosphate; Alleles; AMP Deaminase; Cardiomyopathy, Dilated; Disease Progression; Energy Metabolism; Genetic Predisposition to Disease; Genotype; Heart Failure; Humans; Myocardium; Receptors, Purinergic P1 | 1999 |
Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure.
Topics: Adenosine Monophosphate; Aged; Alleles; AMP Deaminase; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Coronary Disease; Digoxin; Disease Progression; Diuretics; DNA Mutational Analysis; Energy Metabolism; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Genotype; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Oxygen Consumption; Phenotype; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 1999 |